This article is more than 5 years old. Information may no longer be current.
Effective medical therapy still needed for keratoconus patients
MILAN — Transepithelial cross-linking may be an effective new treatment for keratoconus, but an optimal pharmacological formula for management of the disease must still be found, a physician said here.
Theo Seiler, MD, said that physicians must be careful not to attempt too many different treatments in keratoconus patients.
Theo Seiler
"Don't use your patients as guinea pigs to test new [approaches]," he said at the EuCornea congress. "Those patients come to you and trust you. They know you are doing a good job to stop the disease by cross-linking. Don't use suspicious drugs that have not been verified clinically."
Keratoconus management is still a field of experimental study, and physicians must be aware of this when treating patients, he said.
Seiler presented an overview on the evolution of corneal cross-linking, including the original approach, clinical studies, new parameters and new applications in the field.
-
Disclosure: Seiler has no relevant financial disclosures.